ID   MP65
AC   CVCL_4D14
DR   ATCC; CRL-3299
DR   cancercelllines; CVCL_4D14
DR   Wikidata; Q54906431
RX   PubMed=24994677;
CC   Doubling time: 120 hours (PubMed=24994677).
CC   Sequence variation: Mutation; HGNC; HGNC:950; BAP1; Simple; p.Leu573Trpfs*3 (c.1717delC); ClinVar=VCV000221278; Zygosity=Unspecified (PubMed=24994677).
CC   Sequence variation: Mutation; HGNC; HGNC:4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=24994677).
CC   Omics: SNP array analysis.
CC   Derived from site: In situ; Eye, uvea; UBERON=UBERON_0001768.
ST   Source(s): ATCC=CRL-3299; PubMed=24994677
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8 (ATCC=CRL-3299)
ST   D13S317: 8,13 (PubMed=24994677)
ST   D16S539: 11
ST   D21S11: 30,30.2
ST   D5S818: 12
ST   D7S820: 8,11
ST   TH01: 7,9.3
ST   TPOX: 8,12
ST   vWA: 14,18
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   42Y
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 19-12-24; Version: 12
//
RX   PubMed=24994677; DOI=10.1016/j.molonc.2014.06.004; PMCID=PMC5528590;
RA   Amirouchene-Angelozzi N., Nemati F., Gentien D., Nicolas A.,
RA   Dumont A., Carita G., Camonis J., Desjardins L., Cassoux N.,
RA   Piperno-Neumann S., Mariani P., Sastre-Garau X., Decaudin D.,
RA   Roman-Roman S.;
RT   "Establishment of novel cell lines recapitulating the genetic
RT   landscape of uveal melanoma and preclinical validation of mTOR as a
RT   therapeutic target.";
RL   Mol. Oncol. 8:1508-1520(2014).
//